This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n12http://linked.opendata.cz/ontology/domain/vavai/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F11%3A00052780%21RIV12-MSM-14110___/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F11%3A00052780%21RIV12-MSM-14110___
rdf:type
n12:Vysledek skos:Concept
dcterms:description
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non smallcell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients. Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non smallcell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.
dcterms:title
Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
skos:prefLabel
Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
skos:notation
RIV/00216224:14110/11:00052780!RIV12-MSM-14110___
n12:predkladatel
n14:orjk%3A14110
n3:aktivita
n8:V
n3:aktivity
V
n3:dodaniDat
n13:2012
n3:domaciTvurceVysledku
n4:2428245
n3:druhVysledku
n17:O
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n9:predkladatel
n3:idSjednocenehoVysledku
218830
n3:idVysledku
RIV/00216224:14110/11:00052780
n3:jazykVysledku
n16:eng
n3:klicovaSlova
oral vinorelbine; Adjuvant; chemotherapy; short time survival; NSCLC
n3:klicoveSlovo
n6:short%20time%20survival n6:chemotherapy n6:NSCLC n6:oral%20vinorelbine n6:Adjuvant
n3:kontrolniKodProRIV
[A628A7ABB3E0]
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n13:2011
n3:tvurceVysledku
Chalupa, Jiří Grygárková, Ivona Sixtová, Dimka Koubková, Leona Ostřížková, Lenka Kolek, Vítězslav Švecová, Jiřina Skřičková, Jana
n10:organizacniJednotka
14110